Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / From Genome to Multiome
Omics Precision medicine Training and education Molecular Pathology Voices in the Community

From Genome to Multi-ome

Why scientists should rethink rare disease investigation methods

By Neil Ward 02/26/2026 Discussion 5 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Quiz
  • Poll
  • Top Institutions

Share

Top Institutions in Genomic and Multi-omic Research in Rare Diseases

Leading institutions employ cutting-edge genomic technologies including long-read sequencing and multi-omic profiling to resolve complex genetic variants and understand gene regulation in rare diseases. Their multidisciplinary approaches combine clinical genetics, bioinformatics, and molecular biology to enhance diagnostic yield and uncover disease mechanisms.

  • #1

    Broad Institute of MIT and Harvard

    Cambridge, MA

    The Broad Institute is a global leader in genomic research with extensive expertise in rare disease genomics and multi-omic integration, pioneering long-read sequencing applications and large-scale multi-omic datasets to improve rare disease diagnosis.

    Key Differentiators

    • Genomics
    • Rare Disease Research
    • Multi-omics
  • #2

    National Institutes of Health (NIH) - National Human Genome Research Institute (NHGRI)

    Bethesda, MD

    NHGRI spearheads large-scale genomic and epigenomic research initiatives, including multi-omic studies and long-read sequencing projects, with a strong focus on translating genomic discoveries into clinical diagnostics for rare diseases.

    Key Differentiators

    • Genomics
    • Epigenomics
    • Rare Disease Research
  • #3

    University of California, San Francisco (UCSF)

    San Francisco, CA

    UCSF is renowned for its clinical and research programs in rare genetic diseases, integrating genomic and transcriptomic data with epigenetic profiling to enhance diagnostic accuracy and understand disease mechanisms.

    Key Differentiators

    • Genetics
    • Rare Disease Diagnostics
    • Multi-omics
  • #4

    Children’s Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    CHOP combines clinical expertise in pediatric rare diseases with advanced genomic and multi-omic research, utilizing long-read sequencing and epigenomic profiling to improve diagnosis and patient care.

    Key Differentiators

    • Pediatric Genomics
    • Rare Diseases
    • Multi-omics
  • #5

    Wellcome Sanger Institute

    Hinxton, Cambridgeshire

    The Wellcome Sanger Institute is a premier genomics research center with significant contributions to rare disease genomics and multi-omic studies, including the application of long-read sequencing and epigenetic analyses.

    Key Differentiators

    • Genomics
    • Epigenomics
    • Rare Disease Research

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Neil Ward

General Manager EMEA at PacBio, based in Reading, UK.

More Articles by Neil Ward

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.